Description: Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Home Page: www.shuttlepharma.com
SHPH Technical Analysis
One Research Court
Rockville,
MD
20850
United States
Phone:
240 403 4212
Officers
| Name | Title |
|---|---|
| Dr. Anatoly Dritschilo M.D. | Co-Founder, MD, CEO & Chairman |
| Mr. Peter Dale Dritschilo M.B.A., M.D. | Pres & COO |
| Mr. Michael P. Vander Hoek | CFO and VP of Operations & Regulatory |
| Dr. Milton Brown CSC, M.D., Ph.D. | Co-Founder, Chief Scientific Officer for Chemistry & Director |
| Dr. Mira Jung Ph.D. | Co-Founder & Chief Scientific Officer for Biology |
| Mr. Gene Jung Esq. | Gen. Counsel |
| Dr. Tyvin A. Rich M.D. | Chief Clinical Officer |
| Dr. Theodore L. Phillips M.D., Ph.D. | Clinical Director |
| Mr. Michael Jeffrey Starkweather | VP of Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.7319 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-08-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |